Kornimate/medical-research-clean huggingface dataset:
effect of electroacupuncture on refractory pain in juvenile rheumatoid arthritis: randomized controlled trial

Conditions: Juvenile Rheumatoid Arthritis

Summary: the purpose of the study is to investigate the effect of electrical acupuncture versus naproxen phonophoresis on refractory pain in juvenile rheumatoid arthritis

juvenile idiopathic arthritis (jia) is the most common chronic rheumatic disease in children and adolescents, affecting approximately one in 1000 children in north america. it is diagnosed in children younger than 16 years of age with arthritis in one or more joints for at least six weeks after other causes have been excluded. arthritis in jia is characterized by stiffness, pain and swelling of affected joints. the disease course of jia may involve flares of increased disease activity or chronic persistent joint inflammation, even into adulthood. various complications may arise secondary to ongoing disease activity or treatment, including joint damage and deformity, growth abnormalities and osteoporosis with fragility fractures the prevalence of refractory pain in children with arthritis is of particular concern because it often contributes to poor physical and psychosocial outcomes. increased daily symptoms of pain predict considerable functional disability, including significantly reduced participation in school, social and physical activities, and augmented mood disturbance

Eligibility criteria:
inclusion criteria: * • age ranges from 14 to 16 years. * all children will be assigned to the study are suffering from persistent oligoarthritis. * all children have regional knee pain complaint more than 6 weeks. * pain and stiffness especially in the morning, and a joint that feels warm to the touch * low grade fever at the onset of disease exclusion criteria: * • neurological disorders. * dermatological disorders. * acute trauma prior to the study. * other co- morbidities like diabetes and conditions associated with inflammation such as malegnancies. * analgesic drugs or nsaids during the treatment period.

Keywords: refractory pain juvenile rheumatoid arthritis
covid-19 bivalent booster megastudy

Conditions: COVID-19

Summary: this megastudy is a massive randomized controlled trial. by randomizing participants to 10 different intervention conditions simultaneously, the investigators will be able to compare the effectiveness of different interventions to one another and to a control group (in which individuals will only receive the usual communications from their partner organization) to identify which interventions significantly increase vaccination rates. pharmacy customers will be randomly assigned to receive one of the interventions designed by team scientists to encourage vaccination or to a control group. the baseline intervention will be based on the top-performing sms intervention identified in the investigators previous megastudies on encouraging vaccination (milkman et al., 2021b, 2022). pharmacy customers will receive sms messages conveying that a covid booster vaccine is reserved or waiting for them at the pharmacy. additional behavioral science messaging strategies will be tested by building off of this baseline intervention.


Eligibility criteria:
inclusion criteria: • patient of a large retail pharmacy that has opted into receving sms messages from the pharmacy and has received their primary covid vaccination series. exclusion criteria: * the patient unsubscribed from texts before the send date and time of the patient's sms/mms message * the patient received a bivalent covid booster before the send date and time of the patient's sms/mms message.

Keywords: covid-19 vaccination behavioral science interventions vaccination promotion
evaluating radiomorphometric indices and fractal dimension of the pediatric oncology patients on panoramic images

Conditions: Oncology; Bone Loss

Summary: this study evaluated pediatric oncology patients in terms of quality of bone and determine any relation between bone quality and radiotherapy/chemotherapy. the alternative hypothesis is that the bone quality of the oncology patients who received radiotherapy/chemotherapy is lower than the control group.

cancer is the abnormal and uncontrolled proliferation of certain tissues in the body for a reason that cannot be determined yet. childhood cancers occur between 0-17 years of age, and follow-up and treatment of these patients are performed in pediatric oncology services. diagnosis in childhood cancers can be made by clinical examination as well as blood tests and examination of tissue samples. there are also some imaging methods used for diagnosis; ultrasonography, computed tomography, magnetic resonance imaging, positron emission tomography / computed tomography (pet / ct). treatment methods in childhood cancers are as follows; surgery, chemotherapy, radiotherapy and stem cell transplantation. once diagnosed, oncologists and surgeons may choose one of these treatment options by mutual consultation or decide on a treatment method. fractal analysis is a numerical as fractal dimension. trabeculae are thin columns with numerous large spaces that give a honeycomb or spongy appearance of cancellous bone, which is also called trabecular bone or spongy bone. previously, fractal analysis has been reported as a useful method to detect various diseases that affect the trabecular bone structure. particularly in the field of dentistry, studies have shown that fractal analysis by the box-counting method can successfully evaluate trabecular changes in the mandible of patients with osteoporosis and periodontal diseases and in lactating women.

Eligibility criteria:
inclusion criteria: * to have been treated for any oncological diseases in childhood * oncological treatment completed at least one year ago exclusion criteria: * ongoing oncological treatment * patients who unwilling to participate to study

Keywords: pediatric oncology fractal analysis panoramic mandibular indices radiotherapy chemotherapy
incidence of influenza, downstream complications of influenza & hospitalizations in elderly vaccinated with fluarix™

Conditions: Influenza

Summary: this study will investigate the incidence of influenza, disease and various possible downstream complications and hospitalizations or emergency room visits after routine annual vaccination of the elderly population with fluarix™.

this study will investigate the incidence of influenza, disease and various possible downstream complications, such as pneumonia, ischemic hd (unstable angina or mi), congestive heart failure, acute cerebrovascular disease, copd exacerbation and hospitalizations or emergency room visits, and will evaluate the feasibility of health outcome surveillance and the validity of using questionnaires instruments, after routine annual vaccination of the elderly population with fluarix™.

Eligibility criteria:
inclusion criteria all subjects must satisfy to the following criteria at study entry: * (1) a male or female age 65 years at the time of the first vaccination, * (2) subjects who the investigator believes that they can and will comply with the requirements of the protocol (e.g., return for follow-up visits, disease reporting by phone, and completion of questionnaires) should be enrolled in the study * (3) written informed consent obtained from the subject * (4) availability to follow up by phone during the study period * (5) subjects with residence status allowing free mixing with general community. exclusion criteria the subject must not be included in the study for: * (1) history of hypersensitivity to a previous dose of influenza vaccine * (2) history of allergy or reactions likely to be exacerbated by any component of the vaccine including egg, chicken protein, formaldehyde, thimerosal, gentamicin sulfate or sodium deoxycholate, * (3) use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.

Keywords: prophylaxis influenza vaccine
clinical concordance evaluation of t-spot®.tb assay performance (t-cell selecttm study)

Conditions: Tuberculosis

Summary: the objective is to achieve 90% overall, positive and negative clinical concordance between results of the t-spot.tb assay, using cells isolated via density gradient centrifugation and positive selection using the t-cell select kit, between 0-55 hours following venepuncture

in this study, clinical concordance between results of the t-spot.tb assay, using cells stored for 0-8 hours post venepuncture and isolated via density gradient separation and positive selection with magnetic bead isolation using the t-cell selecttm kit will be assessed. concordance between results of the t-spot.tb assay at 0-8 hours post venepuncture and using cells isolated with density gradient centrifugation and results obtained from cells isolated using the t-cell select kit, following storage between 0-55 hours post venepuncture, will be assessed.

Eligibility criteria:
subjects presenting at sites enrolling "suspected of having tb infection" population inclusion criteria * be able to provide informed consent * be able to provide a minimum of 7 ml and maximum of 20 ml of whole blood. * have suspected tb infection. * be at least 18 years of age. * live in a high endemic area for tb infection exclusion criteria • unable to meet inclusion criteria subjects presenting at sites enrolling "no (or minimal) tb risk factors" population inclusion criteria * be able to provide informed consent * be able to provide a minimum of 7 ml and maximum of 20 ml of whole blood. * have no suspicion tb infection. * be at least 18 years of age. * live in low endemic area for tb infection * have no previous medical record of tb infection exclusion criteria * unable to meet inclusion criteria * current/previous tb diagnosis subjects presenting at sites enrolling "low/intermediate tb risk factors" population inclusion criteria * be able to provide a minimum of 7 ml and maximum of 20 ml of whole blood. * have no suspicion tb infection. * be at least 18 years of age. * live in an low/intermediate endemic area for tb infection exclusion criteria * unable to meet inclusion criteria
genetic causes of fsgs, nephrotic syndrome, or kidney failure

Conditions: Focal Segmental Glomerulosclerosis; Nephrotic Syndrome; End Stage Renal Disease; Kidney Failure; Unexplained Proteinuria

Summary: the investigators are trying to learn more about the cause of kidney diseases such as focal segmental glomerulosclerosis (fsgs) and nephrotic syndrome by studying genetics. the investigators are interested in discovering which genes play a role in causing a predisposition to fsgs/ns. the investigators also want to learn why fsgs/ns can run in families. participation in our study involves a saliva sample and a urine sample that you can give from home. there is no cost to participate. all information is kept private and confidential. the investigators also like to include healthy volunteers (parents, spouses) if interested/available but of course this is completely optional.

the investigators welcome anyone (with or without a family history) with unexplained, non syndromic fsgs, nephrotic syndrome, or proteinuria to join the study. participation involves a saliva (or blood if it is preferable) sample and urine sample (if applicable). there is no cost to participate and the study can be done from home in most cases.

Eligibility criteria:
inclusion criteria: * subjects with fsgs (focal segmental glomerulosclerosis) * subjects with ns (nephrotic syndrome) * subjects with unexplained kidney failure (have had a transplant or on dialysis) * subjects with unexplained proteinuria * family members of a person with fsgs, ns, kidney failure, or unexplained protein in their urine * healthy volunteers exclusion criteria: * patients whose kidney disease is already explained by another syndrome such as (branchio oto renal syndrome or alports syndrome) * patients who already know the genetic cause of their kidney disease

Keywords: fsgs ns kidney disease kidney failure renal disease nephrotic syndrome focal segmental glomerulosclerosis familial kidney disease minimal change disease proteinuria
study of bone preservation when osseospeed™ implants are placed immediately following tooth extraction

Conditions: Jaw, Edentulous, Partially

Summary: the purpose of this study is to evaluate the clinical performance of implants placed in individuals who are about to loose one or more of their upper teeth. the main objective is to study how the surrounding bone tissue reacts to two different shapes of implants. clinical performance, in wider terms, means esthetics and long lasting function. half of the patients will receive a cylindrically shaped implant and the other half will receive a conical-cylindrical implant. the implants will be placed and after a healing period of 16 weeks the gum will be re-opened and the bone tissue response clinically evaluated. permanent artificial tooth/teeth will be attached six weeks after that.


Eligibility criteria:
inclusion criteria: * provision of written informed consent * at least 18 years at inclusion * at least 20 teeth with expected functional balanced occlusion after restoration * in need of one or more implants replacing teeth to be removed in the maxilla within region 15 to 25 * presence of an intact extraction socket following removal of the natural tooth defined by: (1) a situation where the marginal border of the facial bone crest deviates less than or equal to 2 mm from that of the expected normal anatomy of the site/region, (2) a marginal border of a potential facial fenestration at least 3 mm apical of the marginal bone crest * presence of an extraction socket anatomy, following removal of the natural tooth, suitable for both cylindrical and conical/cylindrical implants exclusion criteria: * untreated rampant caries and uncontrolled periodontal disease * absence of adjacent (mesial and/or distal) natural tooth root * uncontrolled diabetes (subjects history does not reveal the absence of control of insulin-dependent / non-insulin dependent diabetes mellitus) * current alcohol or drug abuse * systemic or local disease or condition that would compromise post-operative healing and/or osseointegration * need for systemic corticosteroids or any other medication that would compromise post-operative healing and/or osseointegration * history of radiation in the head and neck region * history of chemotherapy within 5 years prior to surgery * unable or unwilling to return for follow-up visits for a period of 3 years and 6 months * unrealistic esthetic demands * unlikely to be able to comply with study procedures according to investigators judgement * involvement in the planning and conduct of the study (applies to both astra tech staff or staff at the investigational site) * previous enrolment in this study

Keywords: replacement of non-restorable single tooth/teeth
application-enabled shared decision-making

Conditions: Breast Cancer; Mastectomy; Breast-Conserving Surgery

Summary: to develop application-enabled shared decision-making among patients with early breast cancer and evaluate the preliminary effects of the interventions.

female breast is an amazing organ that it symbolizes not only the female gender, but also the continuity of human race. in the past treating breast cancer may signal a termination of the breast's predestined role in a woman or a mother. nowadays, surgical treatment of early breast cancer has two options, one is breast-conserving surgery and the other one is total mastectomy. the former treatment option preserves most of the breast tissue but may spare dormant cancer cells in the preserved tissue. the latter treatment option spares no breast tissue and as a result no dormant cancer cells would remain. this treatment dilemma may bother most of the patients especially when they are still under the shade of the bad news. many women are reluctant to discuss their diseased breasts with their folks or even their doctors because of privacy; instead they would seek information through internet. unfortunately, most of their final decision is doctor's preferred choice despite they may have doubts or concerns on doctor's choice of treatment. share decision making (sdm) is a recently developed strategy that allows patients taking part in their treatment plan. patients are invited to join the meeting where doctors explain the latest treatment options and patients express their concerns and finally a decision, both doctors' and patients' concerns well integrated, is reached. one of the drawbacks of sdm is too time consuming; doctors have to prepare a lot of pertinent information, while patients have to try their best to understand the provided information, though many patients may not fully understand their treatment options. it has been reported that a well designed patient decision aids (pdas) could serve as a virtue connection between patients and doctors. instead of merely taking information from the pdas, it allows patients to know all the possible options of treatment and the side effects in an interactive way. it is supposed that patients could be well prepared to discuss with their doctors after interaction with the customized pdas. in taiwan, decision conflict and decision regret are commonly encountered among most cancer patients. the impetus for developing a pdas for female breast cancer patients and evaluating its role on lowering decision conflict and decision regret among these patients comes from the high rates of decision conflict and decision regret among cancer patients in taiwan.

Eligibility criteria:
inclusion criteria: * women, aged \>20 years * newly diagnosed early breast cancer (stages 0-ii) * no surgery yet * no metastases * tumor size \<3 cm exclusion criteria: •tumor located \<2 cm from the nipple

Keywords: early breast cancer surgery shared decision-making m-health application patient decision aid
breathe for hot flashes randomized controlled trial

Conditions: Hot Flashes

Summary: background: paced respiration has been internationally recommended for vasomotor symptom management despite limited empirical evidence. objective: to evaluate efficacy of a paced respiration intervention against a sham comparator breathing control and usual care control for vasomotor and other menopausal symptoms. design: a 16-week, 3-group, partially blinded, controlled trial with 2:2:1 randomization and stratification by group (breast cancer, no cancer), midwestern city and surrounding area. participants: 218 randomized women (96 breast cancer survivors, 122 menopausal women without cancer) recruited through community mailings and registries. interventions: training, home practice support, and instructions to use the breathing at the time of each hot flash were delivered via compact disc with printed booklet (paced respiration intervention) or digital videodisc with printed booklet (fast shallow breathing control). usual care control received a letter regarding group assignment. main measures: hot flash frequency, severity, and bother (primary), hot flash interference in daily life, perceived control over hot flashes, and mood and sleep disturbances (secondary). intervention performance, adherence, and adverse events were assessed.


Eligibility criteria:
inclusion criteria: * at least 18 years of age * reporting daily hot flashes and desirous of hot flash treatment * peri- or post menopausal * living within a 60-mile radius of indianapolis or willing to drive to the center for all study visits * able to read, write, and speak english * in good general health in addition: * breast cancer survivors will have a known diagnosis of non-metastatic disease * no history of other cancers * be at least four weeks post-completion of surgery, radiation and chemotherapy exclusion criteria: * known psychiatric disorders or cognitive impairments * participation in our previous pilot study evaluating our control condition * self-reported difficulties with normal everyday breathing * meet criteria at baseline for number of subjective and/or objective hot flashes

Keywords: menopause breast cancer hot flash night sweats
pemetrexed/cisplatin with or without bevacizumab in brain metastases from non squamous non-small cell lung cancer

Conditions: Non Squamous Non-small Cell Lung Cancer; Brain Metastases; Bevacizumab

Summary: this is a multi-center phase ii randomized controlled study to assess the efficacy of pemetrexed/cisplatin with or without bevacizumab on patients with brain metastasis from non-small cell lung cancer(nsclc) harboring egfr wild type by intracranial pfs(ipfs),also pfs ,dcr and os.the side effect is evaluated as well.


Eligibility criteria:
inclusion criteria: 1. patient who was confirmed stage iv non squamous nsclc with egfr wild type and brain metastases by pathologic histology or cytology 2. patients who had never received therapy (including chemotherapy,wbrt,and bevacizumab) after diagnosed brain metastases 3. appraisable disease, the presence of at least three lesions if longest diameter \<10 mm by brain mri 4. adult patients (≥ 18 years and ≤75 years). ecog performance status 0 or 1 life expectancy of at least 12 weeks.,haemoglobin ³ 10.0 g/dl, absolute neutrophil count (anc) ³1.5 x 109/l, platelets ³ 100 x 109/l. total bilirubin £ 1.5 x upper limit of normal (uln). alt and ast \< 2.5 x uln in the absence of liver metastases, or \< 5 x uln in case of liver metastases. creatinine clearance ³ 60ml/min (calculated according to cockcroft-gault formula). 5. patients should be contraceptive during the period of the trial exclusion criteria: 1. mixed, non-small cell and small cell tumours or mixed adenosquamous carcinomas with a predominant squamous component. 2. history of haemoptysis 3. evidence of tumour invading major blood vessels on imaging. 4. patient was received irradiation of brain. patient with meningeal metastases were confirmed by mri or cytology test of cerebrospinal fluid. 5. previous radiotherapy. 6. serious uncontrolled coagulation disorder or thrombi-embolic complications within 6 months prior to study start or history of serious bleeding complications. 7. major surgical procedures within 4 weeks prior to study entry. 8. minor surgery, including insertion of an indwelling catheter, within 24 hours prior to the first bevacizumab infusion. 9. non-healing wound, active peptic ulcer or bone fracture. 10. history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months of enrollment